Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced the approval of a 2025 A Share Employee Stock Ownership Scheme, which aims to enhance employee motivation and improve company competitiveness. This scheme, which involves existing shares and includes participation from directors and senior management, is designed to foster long-term sustainable growth by aligning the interests of employees with those of the company and its shareholders.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on developing and manufacturing a wide range of pharmaceutical products, with a market emphasis on innovative drug development and healthcare solutions.
Average Trading Volume: 5,972,041
Current Market Cap: HK$457.1B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.